Cabozantinib for sarcoma – pro
t NCCN is significant evidence that this drug is generally accepted in the medical community.
Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, Chevreau C, Duffaud F, Entz-Werlé N, Saada E, Ray-Coquard I, Lervat C, Gaspar N, Marec-Berard P, Pacquement H, Wright J, Toulmonde M, Bessede A, Crombe A, Kind M, Bellera C, Blay JY. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020 Mar;21(3):446-455. doi: 10.1016/S1470-2045(19)30825-3.
Schöffski, Patrick et al, Cabozantinib as an emerging treatment for sarcoma, Current Opinion in Oncology 32(4):p 321-331, July 2020.
NCCN Bone-2, 2023